Total item
Cart Subtotal
$0.00 - Simonowski A, .et al. Differential use of BTK and PLC in FcεRI- and KIT-mediated mast cell activation: A marginal role of BTK upon KIT activation, Biochim Biophys Acta Mol Cell Res, 2019, Dec 11;1867(4):118622 PMID: 31837347
- Carolin N. Zorn, .et al. Stimulus strength determines the BTK-dependence of the SHIP1-deficient phenotype in IgE/antigen-triggered mast cells, Sci Rep, 2018, 8: 15467 PMID: 30341350
- Li T, .et al. Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma, Oncogene, 2018, Nov;37(47):6180-6194 PMID: 30013190
- Brittany M. Duggan, .et al. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia, Sci Rep, 2017, 7: 1578 PMID: 28484277 A
Biological Activity
PCI-32765 is an orally bioavailable small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.
Targets
| Target | Value |
|---|---|
| BTK | IC50: 0.5nM |
| BLK | IC50: 0.5nM |
| Bmx | IC50: 0.8nM |
| CSK | IC50: 2.3nM |
| FGR | IC50: 2.3nM |
| BRK | IC50: 3.3nM |
| Hck | IC50: 3.7nM |
| EGFR | IC50: 5.6nM |
| YES | IC50: 6.5nM |
| ErbB2 | IC50: 9.4nM |
| ITK | IC50: 10.7nM |
| JAK3 | IC50: 16.1nM |
| FRK | IC50: 29.2nM |
| LCK | IC50: 33.2nM |
| RET | IC50: 36.5nM |
| FLT3 | IC50: 73nM |
| TEC | IC50: 78nM |
| Abl | IC50: 86nM |
| Fyn | IC50: 96nM |
| RIPK2 | IC50: 152nM |
| c-Src | IC50: 171nM |
| Lyn | IC50: 200nM |
| PDGFRα | IC50: 718nM |
| Fms | IC50: 5.545μM |
| FER | IC50: 8.07μM |
| JAK1 | IC50: >10μM |
| JAK2 | IC50: >10μM |
| NEK2 | IC50: >10μM |
| p38 | IC50: >10μM |
| PI3K | IC50: >10μM |
| PLK1 | IC50: >10μM |
| RSK1 | IC50: >10μM |
| Syk | IC50: >10μM |
| In vitro (25°C) | DMSO | 88 mg/mL (199.77 mM) | |
| Water | <1 mg/mL (<1 mM) | ||
| Ethanol | <1 mg/mL (<1 mM) | ||
| In vivo | 1% DMSO/30% polyethylene glycol/1% Tween 80 | 12 mg/mL | |
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 22.7 mL | 113.51 mL | 227.01 mL |
| 0.5 mM | 4.54 mL | 22.7 mL | 45.4 mL |
| 1 mM | 2.27 mL | 11.35 mL | 22.7 mL |
| 5 mM | 0.45 mL | 2.27 mL | 4.54 mL |
*The above data is based on the productmolecular weight 440.5 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Catalog Num | A11020 |
|---|---|
| Actions | Inhibitor |
| M. Wt | 440.5 |
| Formula | C25H24N6O2 |
| Solubility | DMSO |
| Purity | >98% |
| Storage | at -20°C 3 years Powder |
| CAS No. | 936563-96-1 |
| Synonyms | Ibrutinib |
| SMILES | C=CC(=O)N1CCC[[email protected]](C1)N2C3=C(C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=NC=N3)N |
Datasheet
Product Tags
Product Questions
Product Questions
No Questions
Keywords:buy PCI-32765 (Ibrutinib) | PCI-32765 (Ibrutinib) Supplier | purchase | cost | manufacturer | order | distributor | buy 936563-96-1| 936563-96-1 Supplier | purchase 936563-96-1 | 936563-96-1 cost | 936563-96-1 manufacturer | order 936563-96-1 | 936563-96-1 distributor
Adooq Quality Guarantee
We promise all products perform as described.